223 related articles for article (PubMed ID: 20627287)
1. Clinical outcomes after radical prostatectomy in diabetic patients treated with metformin.
Patel T; Hruby G; Badani K; Abate-Shen C; McKiernan JM
Urology; 2010 Nov; 76(5):1240-4. PubMed ID: 20627287
[TBL] [Abstract][Full Text] [Related]
2. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome.
Ward JF; Slezak JM; Blute ML; Bergstralh EJ; Zincke H
BJU Int; 2005 Apr; 95(6):751-6. PubMed ID: 15794776
[TBL] [Abstract][Full Text] [Related]
3. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer?
Haukaas SA; Halvorsen OJ; Daehlin L; Hostmark J; Akslen LA
BJU Int; 2006 Jan; 97(1):51-5. PubMed ID: 16336328
[TBL] [Abstract][Full Text] [Related]
4. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.
Han M; Partin AW; Zahurak M; Piantadosi S; Epstein JI; Walsh PC
J Urol; 2003 Feb; 169(2):517-23. PubMed ID: 12544300
[TBL] [Abstract][Full Text] [Related]
5. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy.
Ward JF; Blute ML; Slezak J; Bergstralh EJ; Zincke H
J Urol; 2003 Nov; 170(5):1872-6. PubMed ID: 14532796
[TBL] [Abstract][Full Text] [Related]
6. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F
Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255
[TBL] [Abstract][Full Text] [Related]
7. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
[TBL] [Abstract][Full Text] [Related]
8. Radical prostatectomy for clinical stage T3a disease.
Freedland SJ; Partin AW; Humphreys EB; Mangold LA; Walsh PC
Cancer; 2007 Apr; 109(7):1273-8. PubMed ID: 17315165
[TBL] [Abstract][Full Text] [Related]
9. Association of diabetes mellitus and metformin use with biochemical recurrence in patients treated with radical prostatectomy for prostate cancer.
Rieken M; Kluth LA; Xylinas E; Fajkovic H; Becker A; Karakiewicz PI; Herman M; Lotan Y; Seitz C; Schramek P; Remzi M; Loidl W; Pummer K; Lee RK; Faison T; Scherr DS; Kautzky-Willer A; Bachmann A; Tewari A; Shariat SF
World J Urol; 2014 Aug; 32(4):999-1005. PubMed ID: 24062093
[TBL] [Abstract][Full Text] [Related]
10. Tumour volume is an independent predictor of prostate-specific antigen recurrence in patients undergoing radical prostatectomy for clinically localized prostate cancer.
Nelson BA; Shappell SB; Chang SS; Wells N; Farnham SB; Smith JA; Cookson MS
BJU Int; 2006 Jun; 97(6):1169-72. PubMed ID: 16686706
[TBL] [Abstract][Full Text] [Related]
11. Local control and long-term disease-free survival for stage D1 (T2-T4N1-N2M0) prostate cancer after radical prostatectomy in the PSA era.
Gjertson CK; Asher KP; Sclar JD; Goluboff ET; Olsson CA; Benson MC; McKiernan JM
Urology; 2007 Oct; 70(4):723-7. PubMed ID: 17991544
[TBL] [Abstract][Full Text] [Related]
12. Importance of tumor location in patients with high preoperative prostate specific antigen levels (greater than 20 ng/ml) treated with radical prostatectomy.
Magheli A; Rais-Bahrami S; Peck HJ; Walsh PC; Epstein JI; Trock BJ; Gonzalgo ML
J Urol; 2007 Oct; 178(4 Pt 1):1311-5. PubMed ID: 17698095
[TBL] [Abstract][Full Text] [Related]
13. Do younger men have better biochemical outcomes after radical prostatectomy?
Freedland SJ; Presti JC; Kane CJ; Aronson WJ; Terris MK; Dorey F; Amling CL;
Urology; 2004 Mar; 63(3):518-22. PubMed ID: 15028449
[TBL] [Abstract][Full Text] [Related]
14. Lifelong yearly prostate specific antigen surveillance is not necessary for low risk prostate cancer treated with radical prostatectomy.
Tollefson MK; Blute ML; Rangel LJ; Karnes RJ; Frank I
J Urol; 2010 Sep; 184(3):925-9. PubMed ID: 20643452
[TBL] [Abstract][Full Text] [Related]
15. Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods.
Yossepowitch O; Eggener SE; Bianco FJ; Carver BS; Serio A; Scardino PT; Eastham JA
J Urol; 2007 Aug; 178(2):493-9; discussion 499. PubMed ID: 17561152
[TBL] [Abstract][Full Text] [Related]
16. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era.
D'Amico AV; Whittington R; Malkowicz SB; Cote K; Loffredo M; Schultz D; Chen MH; Tomaszewski JE; Renshaw AA; Wein A; Richie JP
Cancer; 2002 Jul; 95(2):281-6. PubMed ID: 12124827
[TBL] [Abstract][Full Text] [Related]
17. Detectable prostate specific antigen between 60 and 120 days following radical prostatectomy for prostate cancer: natural history and prognostic significance.
Sengupta S; Christensen CM; Zincke H; Slezak JM; Leibovich BC; Bergstralh EJ; Myers RP; Blute ML
J Urol; 2006 Aug; 176(2):559-63. PubMed ID: 16813889
[TBL] [Abstract][Full Text] [Related]
18. Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality.
Freedland SJ; Humphreys EB; Mangold LA; Eisenberger M; Partin AW
J Urol; 2006 Oct; 176(4 Pt 1):1404-8. PubMed ID: 16952644
[TBL] [Abstract][Full Text] [Related]
19. Long-term data on the survival of patients with prostate cancer treated with radical prostatectomy in the prostate-specific antigen era.
Isbarn H; Wanner M; Salomon G; Steuber T; Schlomm T; Köllermann J; Sauter G; Haese A; Heinzer H; Huland H; Graefen M
BJU Int; 2010 Jul; 106(1):37-43. PubMed ID: 20002667
[TBL] [Abstract][Full Text] [Related]
20. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes.
Cookson MS; Aus G; Burnett AL; Canby-Hagino ED; D'Amico AV; Dmochowski RR; Eton DT; Forman JD; Goldenberg SL; Hernandez J; Higano CS; Kraus SR; Moul JW; Tangen C; Thrasher JB; Thompson I
J Urol; 2007 Feb; 177(2):540-5. PubMed ID: 17222629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
